ASTCT HOME MeetingsToxicities Conference

5TH INTERNATIONAL CONFERENCE ON
TOXICITIES OF
TRANSPLANTATION
AND CELLULAR
THERAPIES

November 13-14, 2026

Chicago, Illinois

Key Information Registration Agenda Abstract Submission Supporters

About the Conference

The Toxicities of Transplantation and Cellular Therapies Conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities and symptom burden after hematopoietic cell transplantation (HCT) and cellular therapies; current advances in the field; and best practices to both prevent and treat these toxicities and symptoms.

The program will include a wide range of pre-clinical, translational and clinical topics, will offer networking opportunities and a poster reception showcasing research in toxicities.

Who Should Attend

Physicians, advanced practice providers, nurses and pharmacists who treat or refer patients for HCT or immune effector cell therapies.

Key Information

Topics include:

Current advances in the field and best practices to prevent and treat toxicities and symptoms.
The evolving frontier of allogeneic transplantation in patients aged 75 and older.
Rare but serious CAR T–related toxicities beyond CRS and ICANS.
Emerging challenges in applying cellular therapy to autoimmune diseases and solid tumors.
The integration and application of AI into clinical care and research within HCT and cellular therapies.
The growing importance of managing cardiorenal comorbidities across cellular therapies.

Registration

Type	Early Bird Rate	Regular Rate
Member Rate	$400	$475
Non-Member Rate	$500	$575
Trainee Rate	$300	$375
Industry Rate (Companies Not Sponsoring the Event)	$900	$900

The early bird registration rate ends at 11:59 p.m. CT on Monday, September 14th.

Registration for the conference will close on Thursday, November 12th at 4 p.m. CT. For any registration questions, please email info@astct.org.

Agenda

Day 1: Friday, November 13

6:00 AM	Registration Opens
7:15 – 8:00 AM	Breakfast Product Theater Presented by Iovance
8:10 – 8:15 AM	Welcome to the ASTCT 5th International Conference on Toxicities of Transplantation and Cellular Therapies Christina Cho, MD; Hackensack University Medical Center
8:15 – 9:15 AM	Keynote: Endothelial Cell Damage - A Target for Mitigating Toxicities Stella Davies, MBBS, PhD, MRCP; Cincinnati Children’s
9:15 – 10:55 AM	Main Session 1: 75+: The New Frontier in alloHCT Organizing Committee Session Chairs: Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center and William Wood, MD; University of North Carolina
	Microbiome in Older Adults Undergoing alloHCT Melody Smith, MD, MS; Stanford
	Transplant and Cell Therapy for Octogenarians: What are we doing and what are the outcomes? Doug Rizzo, MD; Medical College of Wisconsin
	Strategies to reduce NRM in older patients: What is most promising and how low can we go? Andrew Artz, MD; City of Hope
	Debate: 75+ RIC alloHCT vs other Mariam Nawas, MD; University of Chicago Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
	Panel Discussion; Q&A
10:55 – 11:10 AM	Break
11:10 AM – 12:50 PM	Main Session 2: Rare but Serious CAR T Toxicities - Beyond CRS & ICANS Session Chair: Nirali Shah, MD, MSc; National Cancer Institute Organizing Committee Session Chair: Melody Smith, MD, MS; Stanford
	IEC-EC Lekha Mikkilineni, MD; Stanford
	TIAN Jasia Mahdi, MD; Texas Children’s
	IEC-HS Nirali Shah, MD, MSc; National Cancer Institute
	Pediatric Specific (NRM/ICAHT/ICANs) Regina Myers, MD, MSCE; Children’s Hospital of Philadelphia
	Panel Discussion; Q&A
12:50 - 1:50 PM	Lunch Break
1:00 - 1:45 PM	Lunch Product Theater Presented by Incyte
1:50 - 3:30 PM	Main Session 3: Matters of the Heart and Kidneys: Cardio-Renal Comorbidity and Toxicity Management Session Chair: Rebecca Olin, MD, MS; UCSF Organizing Committee Session Chair: Mariam Nawas, MD; University of Chicago
	CARE-BMT Alexi Vasbinder, PhD, RN; University of Washington
	PTCy and Cardiac Toxicity Rebecca Olin, MD, MS; UCSF
	CAR T and Lymphodepletion Considerations in Renal Insufficiency Surbhi Sidana, MD; Stanford
	CAR T in Solid Organ Transplant Recipients Samuel Yamshon, MD; NYU Langone Health
	Panel Discussion; Q&A
3:30 -3:45 PM	Break
3:45 - 5:25 PM	Main Session 4: Expanding Frontiers in Cell Therapy: Autoimmune Disease and Solid Tumors — Emerging Toxicities and Challenges Session Chair: Ran Reshef, MD, MSc; Columbia University Organizing Committee Session Chair: Michael Scordo, MD; Memorial Sloan Kettering Cancer Center
	Emergent toxicities and challenges related to cellular therapies for autoimmune diseases Ran Reshef, MD, MSc; Columbia University
	Unique and Specific Toxicities related to TILs Alexandra Haugh, MD, MPH; Massachusetts General Hospital
	Toxicity Challenges in Solid Tumor CAR T Development Saul Priceman, PhD; Keck School of Medicine at USC
	Debate: AutoHCT vs. CAR T in autoimmune disease specifically MS Jeff Dunn, MD; Stanford Guillermo J. Ruiz-Argüelles, MD, FRCP, MACP; Clinica Ruiz
	Panel Discussion; Q&A
5:30 - 6:30 PM	Networking and Poster Reception

Day 2: Saturday, November 14

7:15 – 8:00 AM	Breakfast Product Theater Presented by Johnson & Johnson
8:15 – 9:15 AM	Hype or Help? The Role of AI in Clinical Practice and Discovery Session Chair: Sandeep Raj, MD; Memorial Sloan Kettering Cancer Center Organizing Committee Session Chair: William Wood, MD; University of North Carolina
	Developing and implementing AI-based clinical tools to improve decision-making Sandeep Raj, MD; Memorial Sloan Kettering Cancer Center
	Developing and implementing multi-agentic AI-based tools to accelerate knowledge discovery Vanessa Kennedy, MD; Stanford
	Panel Discussion and Debate - Should the audience embrace AI tools at the bedside and/or in their knowledge discovery workflows? Sandeep Raj, MD; Memorial Sloan Kettering Cancer Center Vanessa Kennedy, MD; Stanford Miguel-Angel Perales, MD; Memorial Sloan Kettering Cancer Center William Wood, MD; University of North Carolina
9:15 – 9:30 AM	Break
9:30 AM – 11:10 AM	Main Session 5: Acute Toxicities and Vulnerabilities in Pediatric Hematopoietic Cell Transplantation Session Chair: Michelle Schoettler, MD; Winship Cancer Institute of Emory University Organizing Committee Session Chair: Christina Cho, MD; Hackensack University Medical Center
	TA-TMA Michelle Schoettler, MD; Winship Cancer Institute of Emory University
	Fertility Management Tyler Ketterl, MD, MS; Seattle Children's Hospital
	Updates in Critical Care Practices and Outcomes in Pediatric HCT Recipients Courtney Rowan, MD; Indiana University/Riley Hospital for Children
	The Use of Pulmonary nNGS and Toxicities Matt Zinter, MD; UCSF
	Panel Discussion; Q&A
11:10 - 11:25 AM	Break
11:25 AM - 12:25 PM	Keynote: How Does a Growing Program Functionally Improve Outcomes by Reducing Toxicities? Shernan Holtan, MD; Roswell Park Comprehensive Cancer Center
12:25 - 12:30 PM	Closing Remarks Michael Scordo, MD; Memorial Sloan Kettering Cancer Center

Housing

The InterContinental Chicago Magnificent Mile

505 N Michigan Ave
Chicago, IL 60611
+1 (312) 944-4100

Registered attendees will receive the housing link to secure discounted room rates in their official registration confirmation email.

Room Rate

$249 plus any applicable taxes and fees (single/double).

Housing Rate Cutoff

To take advantage of the discounted room rate, be sure to book your reservation on or before October 22, 2026 or until rooms are sold out — whichever occurs first. After October 22, the room block will be released and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability.

Deposits

Please have your credit card information on hand upon booking your reservation. The InterContinental Chicago Magnificent Mile requires each individual reservation be guaranteed with a deposit equal to one night's room and tax.

Changes or Cancellations

The InterContinental Chicago Magnificent Mile requires that you cancel your reservation (72) hours prior to your arrival. The deposit of one night's room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records.

Confirmations

The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT. Review it carefully for accuracy and keep a copy for your records.

Abstracts

ASTCT is currently accepting abstracts for the Toxicities Conference, giving you the opportunity to present your research to a broad audience. We welcome abstract submissions from fellows, residents, nurses, APPs, pharmacists, and physicians. The top three best abstracts will receive complimentary registration to the conference. The abstract submission window will close on Tuesday, August 18 at 11:59 p.m. CT.

Submit Your Abstract

Abstract Submission Criteria

Abstracts will be scored based on the following criteria:

Importance and Relevance: Is a clear rationale for the work provided? Does the study address an important question? Do its findings have the potential to advance the field of blood and marrow or cellular therapies?
Originality and Innovation: Is the work novel? Does it present new findings and/or address a problem using an original or improved approach?
Quality of Methods and Writing: Are methods well described and valid to answer the question? Is the abstract clear and well written? Is the abstract within the 300-word limit?

Please note that the abstract submission form does not have a tracker for word count. We recommend that you prepare your abstract submission in a Word document to confirm that you stay within the 300-word limit.

The top three abstracts will receive complimentary registration to the meeting. All accepted abstracts will be required to present their posters at the conference during the poster reception on Friday, November 13.

Responsibility of Abstract Authors

The Presenting Author is responsible for the following:

Ensuring that all authors have read the abstract and agreed to be co-authors.
Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the 5th International Conference on Toxicities of Transplantation and Cellular Therapies.
Obtaining all the conflict-of-interest disclosure information from co-authors.
Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.

Please contact Haedyn Smith with any questions regarding your submission.

Accreditation

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).

TARGET AUDIENCE

This educational activity is intended for physicians, advanced practice providers, and nurses who treat or refer patients for HCT or immune effector cell therapies.

STATEMENT OF NEED

The conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities and symptom burden after hematopoietic cell transplantation (HCT) and cellular therapies; current advances in the field; and best practices to both prevent and treat these toxicities and symptoms.

The program will include a wide range of pre-clinical, translational and clinical topics, will offer networking opportunities and a dedicated poster reception showcasing research in toxicities.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

Analyze mechanisms and drivers of toxicity in HCT and cellular therapies
Evaluate the biological and clinical factors contributing to toxicities in hematopoietic cell transplantation (HCT) and cellular therapies, including aging, frailty, and comorbidities, to improve risk stratification and individualized patient care.
Apply emerging evidence to toxicity prevention and management
Incorporate evolving clinical evidence and therapeutic advances—including recognition of rare CAR T–associated toxicities, cardio-renal complications, and the expanding use of cellular therapies in older adults, autoimmune diseases, and solid tumors—to enhance prevention, early detection, and management strategies.
Assess innovations shaping the future of toxicity monitoring and care
Examine how emerging technologies and translational approaches, including artificial intelligence, biomarker-driven research, and novel monitoring strategies, may improve clinical decision-making, toxicity surveillance, and outcomes in HCT and cellular therapy.

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Physician Credit Designation

The France Foundation designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

Review the activity objectives and CME/CE information.
Participate in the CME/CE activity.
Complete the course evaluation.
If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF And ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

PLANNER, STAFF, AND FACULTY DISCLOSURES

Planner, staff, and faculty disclosures will be available at the conference.

DISCLOSURE OF UNLABELED USE:

TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of

their own clinical judgment and accepted standards of care. The France Foundation, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

Information

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or htarbox@francefoundation.com.

5TH INTERNATIONAL CONFERENCE ON TOXICITIES OF TRANSPLANTATION AND CELLULAR THERAPIES